June 10, 2024 09:00 AM Eastern Daylight Time
Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
View Full Size
Download
Full Size
JPEG, 2908x513, 296.7 KB
Small
JPEG, 480x85, 37.6 KB
Preview
JPEG, 144x25, 7.4 KB
Thumbnail
JPEG, 120x21, 5.7 KB
Smart Multimedia Gallery
Share
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
All News
|
News with Multimedia
>
Press Release: Longboard Pharmaceuticals Announces Positive In...
Get Business Wire News on Your Website
Terms of Use
|
© 2024 Business Wire